Clinical Trials Browser

Terminated × Recurrence × 90 days × Clear all

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04865458 2026-05-14

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Phase 1 Terminated

5 enrolled

Recurrence

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

40 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05815160 2026-05-04

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Terminated

34 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT05861947 2026-04-17

JIVAN

Phase 1 Terminated

21 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT06761586 2026-04-17

VIJAY-1

Phase 1 Terminated

9 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02668770 2026-04-07

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Phase 1 Terminated

28 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Recurrence

NCT06563804 2026-03-30

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Phase 1/2 Terminated

13 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06068400 2026-03-17

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase NA Terminated

1 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

9 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

Clinical Trials

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

MAPtivate-6

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

JIVAN

VIJAY-1

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

NK4AML

ZUMA-25